First Eagle Investment Management
CNST

First Eagle Investment Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

First Eagle Investment Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-28,464
Closed -$350K – 157
2019
Q2 		$350K Sell
28,464
-96,536
-77% -$1.07M ﹤0.01% 146
2019
Q1 		$1.69M Hold
125,000
– – ﹤0.01% 141
2018
Q4 		$501K Buy
+125,000
New +$754K ﹤0.01% 155

Other funds holding CNST

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management's CNST Position: Q3 2019 in Review

First Eagle Investment Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2019, closing a stake of 28,464 shares — an estimated $350K sold.

First Eagle Investment Management first reported a position in CNST in Q4 2018 and held it in 3 quarters. The position peaked at $1.69M in Q1 2019. 48 funds tracked by Wall St. Rank hold CNST as of Q3 2019.

  • First Eagle Investment Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • First Eagle Investment Management sold 28,464 Constellation Pharmaceuticals, Inc. shares in Q3 2019, an estimated $350K.
  • First Eagle Investment Management first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
  • First Eagle Investment Management's Constellation Pharmaceuticals, Inc. position peaked at $1.69M in Q1 2019.
  • 48 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2019.

Based on First Eagle Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.